LOVFF (Cannara Biotech) Stock Based Compensation: $2.44 Mil (TTM As of Feb. 2026)


LOVFF Cannara Biotech Inc LOVFF
85 GF Score
Price $1.31
GF Value $1.17
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Cannara Biotech Stock Based Compensation?

Cannara Biotech LOVFF +1.87% 85 Stock Based Compensation is $2.44 Mil as of Feb. 2026. GuruFocus rates LOVFF with a GF Score™ of 85/100 and a GF Value™ of $1.17 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Cannara Biotech's Stock Based Compensation for the three months ended in Feb. 2026 was $0.80 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Feb. 2026 was $2.44 Mil.

Cannara Biotech Stock Based Compensation Related Terms

Cannara Biotech Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Cannara Biotech's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cannara Biotech Stock Based Compensation Chart

Cannara Biotech Annual Data
Trend Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Stock Based Compensation
Get a 7-Day Free Trial 0.26 0.27 1.30 1.45 0.87

Cannara Biotech Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.19 0.23 1.22 0.80
LOVFF
85GF Score
Cannara Biotech Inc LOVFF
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cannara Biotech Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.44 Mil.

What does a Stock Based Compensation of $2.44 Mil mean?
Cannara Biotech (LOVFF) has a Stock Based Compensation of $2.44 Mil as of Feb. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Cannara Biotech and its competitors.
Is Cannara Biotech's Stock Based Compensation too high?
Cannara Biotech's current Stock Based Compensation is $2.44 Mil. Overall, Cannara Biotech has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's Stock Based Compensation compare to ZTS and UTHR?
Cannara Biotech's Stock Based Compensation of $2.44 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Cannara Biotech and its competitors. Cannara Biotech's current Stock Based Compensation is $2.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (LOVFF) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.17, compared to a current price of $1.31 — trading 12% above its estimated fair value. The current Stock Based Compensation is $2.44 Mil. Cannara Biotech's overall GF Score™ is 85/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Cannara Biotech (LOVFF), the current Stock Based Compensation is $2.44 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cannara Biotech (LOVFF) Overvalued in 2026?

Based on GuruFocus' analysis, Cannara Biotech stock appears to be overvalued. The current stock price of $1.31 is trading 12% above its estimated GF Value™ of $1.17. GuruFocus considers Cannara Biotech to be Modestly Overvalued.

Key valuation signals for LOVFF:

  • Stock Based Compensation: $2.44 Mil
  • GF Value™: $1.17 vs. price of $1.31 (12% above fair value)
  • GF Score™: 85/100 with 5 warning signs

No single metric tells the full story. See the LOVFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cannara Biotech Business Description

Other Exchanges 8CB0:GermanyLOVE:Canada
Address 1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
85GF Score

Get the complete analysis for LOVFF

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.31
Price
$1.17
GF Value